RxDoctor Payments Data

Ann Mojeiko, NP

Nurse Practitioner · Clinton, IANPI 1801463245

Payments from drug & device makers

$2,069in general payments, 2019–2025

Across 125 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$340
  • Otsuka America Pharmaceutical, Inc.$328
  • Teva Pharmaceuticals USA, Inc.$273
  • AbbVie$271
  • Alkermes, Inc.$171
  • E.r. Squibb & Sons, L.L.C.$124
  • plus $562 from 13 others

What the payments were for

  • Food & beverage$2,069100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,069 in reported general payments places this provider in the 90th percentile of 1,346 nurse practitioner providers in Iowa.

See all nurse practitioner providers in Iowa

Medicare billing

Part B allowed, 2024
$27,802
Medicare patients
173
Services billed
678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$31,181
MounjaroTirzepatide12$28,560
XareltoRivaroxaban21$17,756
JanuviaSitagliptin Phosphate12$11,273
EliquisApixaban12$9,566
Dexlansoprazole DrDexlansoprazole20$6,392
SymbicortBudesonide/Formoterol Fumarate11$4,535
Breo ElliptaFluticasone/Vilanterol11$4,487
Clozapine34$4,465
Aripiprazole60$2,637
Albuterol Sulfate HfaAlbuterol Sulfate82$2,506
Bupropion XlBupropion Hcl108$1,868
Atorvastatin Calcium295$1,829
Gabapentin91$1,811
Omeprazole124$1,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$37$31,18130 claims
Johnson & JohnsonXarelto$35$17,75621 claims
MerckJanuvia$21$11,27312 claims
PfizerEliquis$13$9,56612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,346 nurse practitioner providers in Iowa.

Other nurse practitioner in Clinton

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →